Science

AddToAny

Google+ Facebook Twitter Twitter

COVID-19: a report from Melbourne, Australia

Medical Scientist Eileen Kelly reports on the impact of COVID-19 in Melbourne and the way the pandemic has been dealt with.

Melbourne is the second largest city in Australia, with a population of almost five million. It has excellent universities and medical research centres. One of these, the Doherty Institute, named after Peter Doherty, the Nobel Prize winner specialising in immunology, has played a leading role in the story of COVID-19.

Back in January, the main focus of the public mind was on bushfires – Australia had suffered massively and the whole of summer had been one of dread. There is a Royal Commission currently underway to establish what we can do better.

We knew about an outbreak of a coronavirus in Wuhan; there was talk of a SARS-like illness. We tookmore notice when some of our workmates, who had gone home for Chinese New Year, had to self-isolate for two weeks after returning to Melbourne.

The scientists at the Doherty Institute were much more vigilant. They had a test up and running by January 15. A return traveller from China was confirmed to have COVID-19 on January 25. Julien Druce, a senior scientist at the Doherty Institute’s Victorian Infectious Diseases Reference Laboratory (VIDRL), managed to culture the virus. VIDRL uploaded the genome sequence to the international database and shared samples of the virus.

Please click here to read the full article.

Related Articles

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research-CREDIT_istock-1293772951

Equity, diversity and inclusion for all

Jemma Shead, a Senior Biomedical Scientist at Synnovis and IBMS EDI Working Group member, on how and why you should get involved with EDI.

adeno associated virus capsid-Image Credit | Science Photo Library - c0142837

Examining the medical mystery of child hepatitis outbreak

A study has shed light on an unexpected wave of severe acute hepatitis cases in 2022, amid the backdrop of the ongoing global COVID-19 pandemic.

clostridioides difficile bacteria-Image Credit | Science Photo Library - c0016337

Faecal microbiota transplant for C. diff

In the first comprehensive US evidence-based guideline on the use of faecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends faecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.

pseudomonas aeruginosa bacteria Image-Credit | Science Photo Library - f0381226

Tackling priority pathogen with phages

A new study describes the use of phage therapy to eradicate multidrug-resistant Pseudomonas aeruginosa infections in vivo with important new implications for antibiotic resistance.

Top